JNJ

152.36

+0.08%↑

ABBV

185.61

+0.04%↑

NVO

67.33

-4.74%↓

UNH

302.11

-1.12%↓

NVS

117.9

-0.84%↓

JNJ

152.36

+0.08%↑

ABBV

185.61

+0.04%↑

NVO

67.33

-4.74%↓

UNH

302.11

-1.12%↓

NVS

117.9

-0.84%↓

JNJ

152.36

+0.08%↑

ABBV

185.61

+0.04%↑

NVO

67.33

-4.74%↓

UNH

302.11

-1.12%↓

NVS

117.9

-0.84%↓

JNJ

152.36

+0.08%↑

ABBV

185.61

+0.04%↑

NVO

67.33

-4.74%↓

UNH

302.11

-1.12%↓

NVS

117.9

-0.84%↓

JNJ

152.36

+0.08%↑

ABBV

185.61

+0.04%↑

NVO

67.33

-4.74%↓

UNH

302.11

-1.12%↓

NVS

117.9

-0.84%↓

Search

Eli Lilly and Co.

Closed

SectorHealthcare

792.07 1.74

Overview

Share price change

24h

Current

Min

772.08

Max

798.82

Key metrics

By Trading Economics

Income

-6.1B

2.8B

Sales

-804M

13B

P/E

Sector Avg

62.756

50.291

EPS

3.34

Dividend yield

0.79

Profit margin

21.678

Employees

47,000

EBITDA

-2B

4.2B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+28.47% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.79%

2.40%

Next Earnings

6 Aug 2025

Next Dividend date

10 Sept 2025

Next Ex Dividend date

15 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-136B

692B

Previous open

790.33

Previous close

792.07

News Sentiment

By Acuity

40%

60%

132 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Eli Lilly and Co. Chart

Past performance is not a reliable indicator of future results.

Related News

17 Jun 2025, 11:56 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

27 May 2025, 14:41 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

17 Jun 2025, 14:02 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 Jun 2025, 12:12 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 Jun 2025, 11:01 UTC

Acquisitions, Mergers, Takeovers

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 Jun 2025, 10:47 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 Jun 2025, 10:47 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 Jun 2025, 10:46 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 Jun 2025, 10:45 UTC

Acquisitions, Mergers, Takeovers

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 Jun 2025, 09:33 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

11 Jun 2025, 09:45 UTC

Market Talk

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

29 May 2025, 01:00 UTC

Top News

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 May 2025, 18:09 UTC

Earnings

Heart Disease Could Be a Goner When These New -2-

28 May 2025, 18:09 UTC

Earnings

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 May 2025, 14:02 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 May 2025, 14:01 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 May 2025, 14:00 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 May 2025, 14:00 UTC

Acquisitions, Mergers, Takeovers

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 May 2025, 14:08 UTC

Earnings

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 May 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 May 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 May 2025, 17:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 May 2025, 17:01 UTC

Top News

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 May 2025, 13:56 UTC

Earnings

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 May 2025, 11:18 UTC

Earnings

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 May 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6 May 2025, 20:30 UTC

Top News

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4 May 2025, 04:05 UTC

Acquisitions, Mergers, Takeovers

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1 May 2025, 21:07 UTC

Market Talk

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1 May 2025, 14:07 UTC

Earnings

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

Peer Comparison

Price change

Eli Lilly and Co. Forecast

Price Target

By TipRanks

28.47% upside

12 Months Forecast

Average 999.57 USD  28.47%

High 1,190 USD

Low 700 USD

Based on 19 Wall Street analysts offering 12 month price targets forEli Lilly and Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

19 ratings

16

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

N/A / 884.54Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

132 / 380 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.